← Back to Analyst Consensus 
DSGN Buy
Design Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 2, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| May 4, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Mar 16, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Mar 10, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jan 7, 2026 | Oppenheimer | initiate | — → Outperform | $18 | 52% |
| Dec 3, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $14 | 51% |
| Nov 20, 2025 | RBC Capital | upgrade | Sector Perform → Outperform | $13 | 55% |
| Nov 6, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $6 | 55% |
| Aug 6, 2024 | RBC Capital | reiterate | Sector Perform → Sector Perform | $4 | 55% |
| May 7, 2024 | Piper Sandler | upgrade | Neutral → Overweight | $12 | 54% |
| Mar 20, 2024 | RBC Capital | reiterate | Sector Perform → Sector Perform | $4 | 55% |
| Mar 20, 2024 | Wedbush | reiterate | Neutral → Neutral | $5 | 58% |
| Nov 14, 2023 | RBC Capital | maintain | Sector Perform → Sector Perform | $4 | 55% |
| Aug 15, 2023 | Wedbush | downgrade | Outperform → Neutral | $6 | 58% |
| Aug 15, 2023 | SVB Leerink | downgrade | Outperform → Market Perform | $6 | — |
| Aug 15, 2023 | RBC Capital | downgrade | Outperform → Sector Perform | $7 | 55% |
| May 10, 2023 | RBC Capital | maintain | — → Outperform | $23 | 55% |
| May 10, 2023 | Wedbush | maintain | — → Outperform | $19 | 58% |
| May 4, 2023 | Goldman Sachs | upgrade | Sell → Neutral | $0 | 54% |
| Mar 15, 2023 | RBC Capital | reiterate | — → Outperform | $24 | 55% |
| Dec 9, 2022 | SVB Leerink | maintain | — → Outperform | $22 | — |
| Dec 8, 2022 | RBC Capital | maintain | — → Outperform | $24 | 55% |
| Aug 9, 2022 | Wedbush | maintain | — → Outperform | $26 | 58% |
| Jun 10, 2022 | Wedbush | initiate | — → Outperform | $21 | 58% |
| May 24, 2022 | Goldman Sachs | maintain | — → Sell | $6 | 54% |
| May 10, 2022 | SVB Leerink | maintain | — → Outperform | $30 | — |
| May 2, 2022 | RBC Capital | initiate | — → Outperform | $30 | 55% |
| Jan 19, 2022 | Goldman Sachs | initiate | — → Sell | $10 | 54% |
| Apr 20, 2021 | SVB Leerink | initiate | — → Outperform | $36 | — |
| Apr 20, 2021 | Goldman Sachs | initiate | — → Neutral | $28 | 54% |
| Apr 20, 2021 | Piper Sandler | initiate | — → Overweight | $42 | 54% |
Price Target Trend
Apr 1, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days